TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development

Xiao-Shuang Li, Yanmin Wu, Tian TianInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

Metastatic colorectal cancer (mCRC) is a deadly disease with limited treatment options. This review highlights the critical role of the TGF-β signaling pathway in mCRC progression, detailing its mechanisms in promoting metastasis, immune suppression, and stemness. Understanding these pathways offers new avenues for targeted therapies and personalized medicine in mCRC treatment.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a major global health concern, and when it metastasizes (mCRC), the prognosis becomes significantly worse, with high mortality rates. Current treatments often fall short for these advanced cases. The paper addresses the urgent need to understand the complex molecular mechanisms driving mCRC to develop more effective therapeutic strategies. Specifically, it focuses on the Transforming Growth Factor-beta (TGF-β) signaling pathway, a known player in various cellular processes, and its aberrant role in the progression and spread of colorectal cancer.

Methods

This paper is a comprehensive review, not an experimental study. It synthesizes existing research from a wide range of sources, including genetic studies, molecular analyses, and clinical observations. The authors systematically review published literature to:

  • Summarize alterations in the TGF-β signaling pathway observed in mCRC patients.
  • Elucidate the functional mechanisms by which TGF-β signaling contributes to mCRC, including its impact on epithelial-mesenchymal transition (EMT), angiogenesis, the tumor microenvironment (TME), and cancer stemness.
  • Discuss potential applications of targeting TGF-β signaling for diagnosis, prognosis, and therapeutic development in mCRC.

Datasets

Not discussed in the paper. As a review article, it analyzes existing data and findings from numerous studies rather than generating new datasets.

Key Insights and Ideas

  • The TGF-β Paradox: While TGF-β can suppress tumor growth in early stages, it paradoxically promotes tumor progression and metastasis in later stages of cancer, including CRC. This dual role makes it a complex but crucial target.
  • Multifaceted Role in Metastasis: TGF-β isn't a single-trick pony in mCRC. It orchestrates multiple processes essential for cancer spread:
  • EMT: It drives epithelial cells to become more mobile and invasive.
  • Angiogenesis: It promotes the formation of new blood vessels to supply tumors and facilitate their entry into circulation.
  • Immunosuppression: It creates a "cold" tumor microenvironment, dampening the anti-tumor immune response.
  • Stemness: It supports the self-renewal and resistance of cancer stem cells, which are key drivers of recurrence and metastasis.
  • Aberrant Signaling is Common: Mutations and alterations in TGF-β receptors (like TGFBR1 and TGFBR2) and downstream signaling molecules (SMADs) are frequently observed in mCRC, underscoring the pathway's importance.
  • Targeting is Promising: The review identifies various components of the TGF-β pathway (ligands, receptors, SMADs, and even regulatory molecules like miRNAs and lncRNAs) as potential targets for novel therapies.
  • Personalized Medicine Potential: Given the heterogeneity of CRC and individual patient differences, understanding specific TGF-β pathway alterations could pave the way for personalized treatment strategies, particularly for the aggressive CMS4 subtype.

Key Results

The paper doesn't present quantitative results in the traditional sense, but its key findings are qualitative and mechanistic:

  • Detailed descriptions of how TGF-β signaling components (ligands, receptors, SMADs) are altered in mCRC.
  • Elucidation of the molecular mechanisms through which TGF-β drives EMT, angiogenesis, immune evasion, and stemness in mCRC cells.
  • Identification of numerous molecular players within the TGF-β pathway that are implicated in mCRC progression and could serve as therapeutic targets.
  • Evidence suggesting that targeting TGF-β signaling, potentially in combination with other therapies, holds promise for improving mCRC outcomes.

Limitations and Future Work

  • TGF-β Paradox Complexity: The dual role of TGF-β in cancer (suppression vs. promotion) remains a challenge for therapeutic development, requiring careful consideration of timing and context.
  • Heterogeneity of mCRC: The significant genetic heterogeneity among mCRC patients and within tumors necessitates personalized approaches, making a one-size-fits-all therapy unlikely.
  • Tumor Microenvironment Complexity: TGF-β signaling's intricate interactions with various cells (CAFs, immune cells) within the TME require further in-depth study.
  • Future Directions:
    • Develop targeted therapies that specifically inhibit the pro-metastatic functions of TGF-β while minimizing its tumor-suppressive roles.
  • Explore combination therapies that leverage TGF-β inhibitors with immunotherapy or traditional chemotherapy to overcome resistance and enhance efficacy.
  • Utilize next-generation sequencing (NGS) and genetic profiling to identify molecular subtypes of TGF-β signaling in mCRC patients, enabling personalized treatment selection.
  • Further investigate the role of non-canonical TGF-β pathways and crosstalk with other signaling cascades.

Summary updated

Abstract

Colorectal cancer (CRC) is a serious public health issue, and it has the leading incidence and mortality among malignant tumors worldwide. CRC patients with metastasis in the liver, lung or other distant sites always have poor prognosis. Thus, there is an urgent need to discover the underlying mechanisms of metastatic colorectal cancer (mCRC) and to develop optimal therapy for mCRC. Transforming growth factor-β (TGF-β) signaling plays a significant role in various physiologic and pathologic processes, and aberrant TGF-β signal transduction contributes to mCRC progression. In this review, we summarize the alterations of the TGF-β signaling pathway in mCRC patients, the functional mechanisms of TGF-β signaling, its promotion of epithelial-mesenchymal transition, its facilitation of angiogenesis, its suppression of anti-tumor activity of immune cells in the microenvironment and its contribution to stemness of CRC cells. We also discuss the possible applications of TGF-β signaling in mCRC diagnosis, prognosis and targeted therapies in clinical trials. Hopefully, these research advances in TGF-β signaling in mCRC will improve the development of new strategies that can be combined with molecular targeted therapy, immunotherapy and traditional therapies to achieve better efficacy and benefit mCRC patients in the near future.
BibTeX
@article{li2022tgf,
  author = {Xiao-Shuang Li and Yanmin Wu and Tian Tian},
  title = {{TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms232214436},
}
Figure